Milestone Pharmaceuticals (MIST) Earnings Analysis

Milestone Pharmaceuticals (MIST) next reports earnings on 2026-08-12, consensus EPS -0.18 USD. Last quarter (2026-03-20) it beat with EPS -0.16 USD vs -0.18 USD est (+11.1%). It has beaten estimates in 2/4 recent quarters (50%). Trailing P/E -1.75.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does MIST next report earnings?

Next earnings date2026-08-12
Consensus EPS estimate-0.18 USD
Revenue estimate0.00B

MIST earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-20-0.16 USD-0.18 USD+11.1%Beat
2025-11-12-0.12 USD-0.17 USD+29.4%Beat
2025-08-12-0.2 USD-0.18 USD-11.1%Miss
2025-03-13-0.19 USD-0.15 USD-26.7%Miss

Beat rate: 2/4 (50%) over reported quarters with consensus data.

MIST valuation and analyst view

Trailing P/E-1.75
Trailing EPS-0.52471 USD
Price / book4.30
Dividend yield0.00%
Market cap0.10B
Analyst consensusBuy (6 buy / 1 hold / 0 sell)
Avg price target7.33 USD

Related research pages

Frequently asked questions

When is Milestone Pharmaceuticals (MIST)'s next earnings date?

Milestone Pharmaceuticals is next scheduled to report on 2026-08-12, with a consensus EPS estimate of -0.18 USD and revenue estimate of 0.00B.

Did MIST beat earnings last quarter?

In its 2026-03-20 report, MIST posted EPS of -0.16 USD versus a -0.18 USD estimate — a beat of 11.1%.

What is MIST's earnings track record?

Over the last 4 reported quarters with consensus data, MIST beat estimates 2 times (50%).

What is MIST's current P/E ratio and EPS?

MIST trades at a trailing P/E of -1.75 on trailing EPS of -0.5247147251770264 USD.

What do analysts rate MIST?

Analyst consensus is "Buy" across 7 ratings (0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 7.33 USD.